Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

Trial Profile

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARX 788 (Primary) ; Cemiplimab (Primary) ; Dostarlimab (Primary) ; Durvalumab (Primary) ; Encequidar+paclitaxel-Athenex (Primary) ; Endoxifen (Primary) ; Evorpacept (Primary) ; Fianlimab (Primary) ; Ganetespib (Primary) ; Ganitumab (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Lasofoxifene (Primary) ; Letrozole (Primary) ; MK 2206 (Primary) ; Nelitolimod (Primary) ; Neratinib (Primary) ; Olaparib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Talazoparib (Primary) ; Trastuzumab (Primary) ; Trastuzumab-duocarmazine (Primary) ; Trebananib (Primary) ; Trilaciclib (Primary) ; Tucatinib (Primary) ; Veliparib (Primary) ; Vepdegestrant (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Trastuzumab emtansine
  • Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms I-SPY; I-SPY 2.2 TRIAL; I-SPY-2; I-SPY2; SURMOUNT
  • Most Recent Events

    • 21 Mar 2024 According to Agendia media release, the company announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
    • 18 Dec 2023 Results (n=134) assessing Efficacy and biomarker discovery of Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer published in the Clinical Cancer Research
    • 24 Oct 2023 Results assessing reduction of anthracycline use with a combined imaging and pathology prediction models using retrospective I-SPY data and prospectively tested in I-SPY2 presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top